Drug intelligence / Profile preview

ABO-701

Development stage: Preclinical
Lead developer: Abeona Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ABO-701 is an autologous CAR-T cell therapy being developed by Abeona Therapeutics for the treatment of advanced prostate cancer. It utilizes the SIR-T™ (Selectively Inhibitable Receptors for T-cells) platform, which is licensed from Angeles Therapeutics. The therapy targets Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed on prostate cancer cells. In preclinical studies, ABO-701 has shown durable tumor control in mouse models with manageable cytokine release profiles. Abeona Therapeutics plans to file an Investigational New Drug (IND) application and initiate first-in-human clinical trials in the second half of 2027.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on ABO-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABO-701.

Explore the full profile